2J 萨姆布鲁克,D W 弗里奇,著.黄培堂等译.分子克隆实验指南.第3版,北京:科学出版社,2002.26-96.
3Shariff MI, Cox IJ, Gomaa AI, et al. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol, 2009,3 : 353 -367.
4Masuzaki R, Karp SJ, Omata M. New serum markers of hepatocellular carcinoma. Semin Oncol, 2012,39:434-439.
5Zhou Y, Yin X, Ying J, et al. Golgi protein 73 versus alpha- fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. BMC Cancer, 2012,16 : 12 : 17.
6Ozkan H, Erdal H, Tutkak H, et al. Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma. Digestion, 2011,83:83-88.
7Maini M K, Boni C, Lee C K et al. The role of virus-specific CD8 ( + ) cells in liver damage and viral contl during persistent hepatitis B virus infection[J]. J Exp Med, 2000 , 191 (8) : 1269-1280.
8Mondelli M U, Varchetta S, Oliviero B. Natural killer cells in viral hepatitis: facts and controversies[ J]. Eur J Clin Invest, 2010, ,40 (9) : 851-863.
9Bertoletti A, Maini M K, Ferrari C. The host-pathogen interaction during HBV infection : immunological controversies [ J ]. Antivir T- her, 2010, 15(suppl3) : 15-24.
10Zhu J, Yamane H, Paul W E. Differentiation of effector CD4 T cell populations[ J]. Annu Rev Immunol, 2010 , 28:445489.
